FUSION PROTEIN OF MUTATED SINGLE-CHAIN HUMAN COAGULATION FACTOR VIII, PREPARATION METHOD THEREFOR, AND USE THEREOF

Disclosed is a fusion protein of a mutated recombinant single-chain human coagulation factor VIII (FVIII), a preparation method therefor, and a use thereof. The fusion protein sequentially comprises, from an N-terminus to a C-terminus, a mutated single-chain human FVIII having a partially deleted B-...

Full description

Saved in:
Bibliographic Details
Main Authors Gao, Yongjuan, Chen, Si, Jia, Shixiang, Jin, Yingying, Dong, Zhao, Li, Qiang, Zheng, Yuncheng, Sun, Bill Nai-chau, Wang, Zhu
Format Patent
LanguageEnglish
Published 03.02.2022
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:Disclosed is a fusion protein of a mutated recombinant single-chain human coagulation factor VIII (FVIII), a preparation method therefor, and a use thereof. The fusion protein sequentially comprises, from an N-terminus to a C-terminus, a mutated single-chain human FVIII having a partially deleted B-domain, a flexible peptide linker, at least one rigid unit of a carboxyl-terminal peptide of a human chorionic gonadotropin beta subunit, and a half-life prolonging moiety (preferably an IgG Fc variant). The fusion protein has a similar biological activity to a recombinant FVIII, a prolonged active half life in vivo, and better stability in vitro and in vivo, and thus improves the pharmacokinetics and efficacy of the fusion protein.
Bibliography:Application Number: US201917280343